Genomic Evolution of Ibrutinib Resistant Clones in Waldenström Macroglobulinemia

Ibrutinib is highly active in Waldenström macroglobulinemia (WM) patients, but disease progression can occur due to acquired mutations in BTK, the target of ibrutinib, or PLCG2, the protein downstream BTK. However, not all resistant patients harbour these alterations. We have performed a whole exome...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Jiménez, Cristina, Chan, Gloria G., Xu, Lian, Tsakmaklis, Nickolas, Kofides, Amanda, Demos, Maria G., Chen, Jiaji, Liu, Xia, Munshi, Manit, Yang, Guang, Castillo, Jorge J., Wiestner, Adrian, García- Sanz, Ramón, Treon, Steven P., Hunter, Zachary R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7299825/
https://ncbi.nlm.nih.gov/pubmed/32103491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.16463
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados